Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Malignant Tumor of Pancreas Metastatic to Liver 1

Interventions

Oxaliplatin 5Leucovorin 5Fluorouracil 5Gemcitabine 4pirarubicin 2liposomal doxorubicin 2Surgical Procedures, Operative 2Radiation 2Paclitaxel 2Neoadjuvant Therapy 2Folfox protocol 2Capecitabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2vocimagene amiretrorepvec 1taxane 1sulindac sulfone 1remdesivir 1pembrolizumab 1nimotuzumab 1methylnaltrexone 1lenvatinib 1irinotecan sucrosofate 1carbon-11 acetate 1bavituximab 1alovudine 1aflibercept 1Thyroxine 1Therapeutics 1Temozolomide 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × irinotecan sucrosofate × Clear all
NCT04037241 2022-04-01

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Sorrento Therapeutics, Inc.

Phase 2/3 Withdrawn
Gastrointestinal

Malignant Tumor of Pancreas Metastatic to Liver

Data powered by HemOnc (CC BY 4.0) Colophon âš¡